Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CG 0070

Drug Profile

CG 0070

Alternative Names: CG0070

Latest Information Update: 12 Feb 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cell Genesys; Genetic Therapy
  • Developer Cold Genesys
  • Class Antineoplastics; Oncolytic viruses
  • Mechanism of Action Cell death stimulants; Granulocyte macrophage colony stimulating factor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Bladder cancer

Most Recent Events

  • 12 Feb 2019 Cold Genesy withdraws a phase II trial for Bladder cancer in USA (NCT02143804)
  • 04 Dec 2018 Preclinical trials in Bladder cancer (Combination therapy) in USA (Intravesicular) (Cold Genesys pipeline, December 2018)
  • 01 Dec 2018 Cold Genesys completes the phase II BOND2 trial for Bladder cancer (Second-line therapy or greater) in USA (NCT02365818)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top